| Name | Title | Contact Details |
|---|
FMI is a full-service contract manufacturing company established in 1992, specializing in the formulation, manufacturing, and packaging of prestige products in the personal care, home care, and fragrance markets. They provide a comprehensive range of services, including product development, formulation, manufacturing, filling, warehousing, shipping, and third-party logistics. This allows clients to efficiently bring their products to market with personalized attention. FMIs expertise covers a wide array of products, such as skin care items, fragrances, cleaning products, sun care solutions, air fresheners, mens grooming products, laundry detergents, dietary supplements, hair care, lip balm packaging, and bath and shower essentials. They position themselves as a key partner for beauty and personal care companies, offering the capabilities of a large manufacturer combined with the personal touch of a smaller company. Their clients benefit from a hassle-free process from initial product conception to final delivery.
Flynn Group is the largest franchise operator in the United States, focusing on multi-brand restaurant and retail operations. Founded in 1999 by Greg Flynn, the company has expanded significantly from its beginnings as a single-market Applebee’s operator. It now manages a diverse portfolio that includes well-known brands such as Pizza Hut, Taco Bell, Panera Bread, and Arby’s, with over 2,500 locations across the country. The company specializes in franchise management, acquiring and optimizing underperforming locations to enhance operational efficiency and drive sales growth. Flynn Groups acquisition strategy has led to substantial growth, including the recent addition of 45 Pizza Hut locations in 2025, bringing its total to over 1,000. With a people-first approach, Flynn Group emphasizes employee training and retention, ensuring consistent customer experiences across its various dining segments.
Smardt Chiller Group is a global leader in oil-free centrifugal chiller technology, focusing on high-efficiency HVAC solutions for commercial, industrial, and institutional applications. Founded in 2005 by Roger Richmond-Smith and Ron Conry, the company has over 25 years of experience in magnetic bearing compressors and oil-free systems. Smardt operates manufacturing facilities in Canada, the USA, Australia, Germany, and China, with more than 10,000 chillers installed worldwide. The company offers a range of products, including water-cooled, air-cooled, and evaporative-cooled chillers, as well as customizable modular systems. All chillers utilize oil-free centrifugal compressors with magnetic bearings, which enhance energy efficiency and reduce maintenance needs. Smardt also provides custom engineering, global support for installation and maintenance, and energy efficiency consulting to help clients optimize their systems and reduce carbon footprints. The company serves various industries, including government facilities, pharmaceutical manufacturing, data centers, and hospitals, emphasizing reliability and sustainability in its solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.